Companies /Healthcare

United Therapeutics Corp

NASDAQ: UTHR Drug Manufacturers - Specialty & Generic
$559.10
▼ $18.24 (−3.16%) today
Markets closed · 2:17am ET

24/7 Wall St. View

UTHR at a Glance

Valuation
Market cap
$23.8B
P/E ratio
21.1
Profitability
Revenue (TTM)
$3.2B
Profit margin
38.6%
EPS (TTM)
$26.49
Price
52-week range
$456 – $614
24/7 target
$733.67
Street target
$687.14
Earnings
Q3 2026 EPS
$5.71
vs. $6.04 est.
−5.5%

Headquartered in Silver Spring, MD Fiscal year ends December NASDAQ: UTHR unither.com

About United Therapeutics

United Therapeutics Corporation is a public benefit corporation that develops and commercializes therapies for rare diseases, chiefly pulmonary arterial hypertension (PAH). It is also developing manufactured organs and organ alternatives to expand the supply of transplantable organs.

Its commercial PAH portfolio includes:
- Tyvaso DPI (inhaled dry powder treprostinil)
- Nebulized Tyvaso
- Remodulin (infused treprostinil, with the Remunity and RemunityPRO pump systems)
- Orenitram (oral treprostinil)
- Adcirca (tadalafil, a trademark of Eli Lilly and Company, sold by the company)

It also sells Unituxin, an oncology product. Revenue is overwhelmingly generated in the United States, with Tyvaso products accounting for the majority of sales.

The company invests heavily in R&D across cardiopulmonary and respiratory medicine and in manufactured organ projects. It recently acquired Thymmune Therapeutics, Inc. in an asset acquisition. The company returns capital through large share repurchase programs, including accelerated share repurchases with Citibank. In October 2026 it settled patent litigation with Liquidia Technologies, Inc. and Sandoz. The company was founded by CEO Martine Rothblatt. Updated

Revenue by Segment · Q3 2026
  1. Tyvaso DPI45%
  2. Orenitram17%
  3. Nebulized Tyvaso15%
  4. Remodulin15%
  5. Unituxin6%
  6. Adcirca1%

Latest Activity

UTHRUnited Therapeutics
Q3 2026
EPS
$5.71
est $6.04-5.5%
Revenue
$833M
est $781M+6.6%

Record quarterly revenue came in well ahead of estimates on 13% growth in Tyvaso DPI, yet earnings missed because a $130 million nondeductible charge for the Thymmune acquisition pushed the tax rate to 31% from 23%. The miss traces to that pipeline bill rather than demand, and management just authorized another $2.0 billion buyback.

Quarterly EPS — reported vs estimate

UTHR Coverage

Frequently Asked Questions

What does United Therapeutics do?

United Therapeutics Corporation is a public benefit corporation that develops and commercializes therapies for rare diseases, chiefly pulmonary arterial hypertension (PAH). It is also developing manufactured organs and organ alternatives to expand the supply of transplantable organs.

What is the UTHR stock price target?

24/7 Wall St.'s 12-month price target for UTHR is $733.67, rated Buy. The Wall Street consensus target is $687.14. UTHR price prediction →